12 completed. 12 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 12 |
| Phase 2 | 2 | Completed 2 |
Follow Glomerulonephritis, IGA: new trials by email Literature Review of Glomerulonephritis, IGA trials Research Report on Glomerulonephritis, IGA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects HRS-5965 Capsules - IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 16 | 2025-06-30 | 2025-08-20 |
| Study of ARO-CFB in Adult Healthy Volunteers ARO-CFB, Placebo - IgA Nephropathy | Phase 1 | Completed | Arrowhead Pharmaceuticals | 49 | 2024-04-05 | 2026-05-20 |
| Relative Bioavailability Study of HR19042 in Healthy Subjects HR19042 Capsule, Tarpeyo®, Budenofalk® - Primary IgA Nephropathy; Autoimmune Hepatitis | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 18 | 2023-12-27 | 2025-04-22 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject SHR-2010 injection, SHR-2010 injection placebo - IgA Nephropathy | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 61 | 2022-06-30 | 2023-03-23 |
| Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria ALXN1720 - Proteinuria | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2022-06-29 | 2023-06-29 |
| Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease ARO-C3, Placebo - C3 Glomerulopathy, IgA Nephropathy | Phase 1 / Phase 2 | Completed | Arrowhead Pharmaceuticals | 62 | 2022-02-01 | 2026-05-22 |
| A Trial of HR19042 Capsule in Healthy Chinese Subjects HR19042 capsule - Primary IgA Nephropathy | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 12 | 2021-07-01 | 2021-09-24 |
| Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension RE-021, sparsentan - Healthy Subjects | Phase 1 | Completed | Travere Therapeutics, Inc. | 47 | 2020-06-18 | 2022-09-30 |
| The Clinical Trial of ADR-001 for IgA Nephropathy infusion of ADR-001 (Mesenchymal stem cell) - Glomerulonephritis , IGA | Phase 1 | Completed | Nagoya University | 9 | 2020-06-15 | 2023-05-01 |
| Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) BION-1301 Single Dose, Placebo Single Dose, BION-1301 Multiple Doses - IgA Nephropathy | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 103 | 2019-04-08 | 2026-06-16 |
| First in Human Study to Assess Safety of VIS649 in Healthy Subjects VIS649, Placebo - Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 51 | 2018-10-09 | 2026-05-01 |
| A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications CCX168, Midazolam, Celecoxib - Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 1 | Completed | Amgen | 32 | 2016-01-14 | 2023-08-22 |
Glomerulosclerosis, Focal Segmental (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Atypical Hemolytic Uremic Syndrome (1) · Diabetic Nephropathies (1) · Glomerulonephritis, Membranoproliferative (1) · Hematuria, Benign Familial (1) · Hemoglobinuria, Paroxysmal (1) · Hepatitis, Autoimmune (1) · Kidney Diseases (1) · Lupus Nephritis (1) · Nephrosis, Lipoid (1) · Proteinuria (1) · Renal Insufficiency, Chronic (1)
Autoimmune Diseases (12) · Female Urogenital Diseases (12) · Female Urogenital Diseases and Pregnancy Complications (12) · Glomerulonephritis (12) · Immune System Diseases (12) · Male Urogenital Diseases (12) · Nephritis (12) · Urogenital Diseases (12) · Urologic Diseases (12) · Kidney Diseases (11) · Anemia (2) · Anemia, Hemolytic (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Skin and Connective Tissue Diseases (2)
Budesonide (1) · Celecoxib (1) · Itraconazole (1) · Midazolam (1) · Rifampin (1) · avacopan (1) · sparsentan (1)
Arrowhead Pharmaceuticals (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Alexion Pharmaceuticals, Inc. (1) · Amgen (1) · Chengdu Suncadia Medicine Co., Ltd. (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Nagoya University (1) · Novartis Pharmaceuticals (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Travere Therapeutics, Inc. (1)
China (4) · South Korea (3) · United Kingdom (3) · United States (3) · New Zealand (2) · Australia (1) · Georgia (1) · Germany (1) · Japan (1) · Thailand (1)
Esther Yoon, MD (1) · Shoichi Maruyama, MD, PhD (1)
PMID 38299639, PMID 35570983, PMID 35692547, PMID 39186380, PMID 40297949, PMID 40482854, PMID 40936477, PMID 41805697, PMID 42275148
2018 (1), 2023 (1)